Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

HTFL

Heartflow Inc

May 13 • 04:00PM ET

31.20

+1.78 6.05 %

Healthcare • Health Information Services • USA • Mid • NASD

Today, 3:02 PMEarnings anticipation and upward estimate revisions propel HTFL higher ahead of Q1 report.

Peers: GDRX PHR CERT TDOC TEM

| Held by: VTI VB VBR IWM VXF FBCG IWO SCHA VTWO IWN

Index	RUT	P/E	-	EPS (ttm)	-1.40	Insider Own	26.71%	Shs Outstand	85.28M	Perf Week	3.00%
Market Cap	2.68B	Forward P/E	-	EPS next Y	-0.33	Insider Trans	-15.69%	Shs Float	62.85M	Perf Month	7.40%
Enterprise Value	2.52B	PEG	-	EPS next Q	-0.19	Inst Own	57.08%	Short Float	6.94%	Perf Quarter	15.77%
Income	-116.79M	P/S	15.20	EPS this Y	65.70%	Inst Trans	10.42%	Short Ratio	3.22	Perf Half Y	-7.77%
Sales	176.03M	P/B	8.85	EPS next Y	40.58%	ROA	-	Short Interest	4.36M	Perf YTD	7.03%
Book/sh	3.53	P/C	15.13	EPS next 5Y	-	ROE	-	52W High	41.22 -24.31%	Perf Year	-
Cash/sh	2.06	P/FCF	-	EPS past 3/5Y	5.20% -	ROIC	-36.87%	52W Low	20.13 54.99%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	42.10% -	Gross Margin	76.80%	Volatility	5.54% 5.32%	Perf 5Y	-
Dividend TTM	-	EV/Sales	14.32	EPS Y/Y TTM	-	Oper. Margin	-36.39%	ATR (14)	1.65	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.04	Sales Y/Y TTM	-	Profit Margin	-66.35%	RSI (14)	60.37	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	5.04	EPS Q/Q	-10.93%	SMA20	2.65%	Beta	-	Target Price	37.67
Payout	-	Debt/Eq	0.07	Sales Q/Q	83.03%	SMA50	14.70%	Rel Volume	0.69	Prev Close	29.42
Employees	843	LT Debt/Eq	0.05	Earnings	May 14 AMC	SMA200	3.59%	Avg Volume	1.35M	Price	31.20
IPO	Aug 08, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	29.04% 5.48%	Trades		Volume	927,366	Change	6.05%

Date	Action	Analyst	Rating Change	Price Target Change
May-04-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Wells Fargo	Overweight	$38
Sep-02-25	Initiated	Stifel	Buy	$35
Sep-02-25	Initiated	Piper Sandler	Overweight	$38
Sep-02-25	Initiated	Morgan Stanley	Equal-Weight	$35
Sep-02-25	Initiated	JP Morgan	Overweight	$36
Sep-02-25	Initiated	Canaccord Genuity	Buy	$35

Today 09:16AM	What To Expect From HeartFlow Inc (HTFL) Q1 2026 Earnings (GuruFocus.com) +6.05%
Apr-23-26 04:05PM	Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026 (GlobeNewswire) -5.13%
Apr-13-26 08:30AM	Heartflow Files Patent Infringement Lawsuit Against Cleerly (GlobeNewswire)
Mar-27-26 09:30AM	How Decentralized AI is Unlocking Value in Cardiac Diagnostics (PR Newswire)
Mar-18-26 11:00PM	HeartFlow Inc (HTFL) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com) +13.10%
04:22PM	Loading…
04:22PM	HeartFlow: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-17-26 09:18AM	Earnings To Watch: HeartFlow Inc (HTFL) Reports Q4 2025 Result (GuruFocus.com) +7.34%
Mar-16-26 08:00AM	Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning (GlobeNewswire)
Feb-25-26 01:26AM	Heartflow, Inc. (HTFL) Announces an Expansion of its GAMEFILM Registry (Insider Monkey)
Feb-18-26 04:05PM	Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference (GlobeNewswire) +6.33%
Feb-13-26 04:21PM	Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 (GlobeNewswire) -8.14% +7.79%
Feb-12-26 08:00AM	Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes (GlobeNewswire) -16.55%
Jan-29-26 09:41AM	PayPal downgraded, UPS upgraded: Wall Streets top analyst calls (TipRanks)
Jan-28-26 09:39AM	PayPal downgraded, UPS upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Loading…
Jan-06-26 08:00AM	Heartflow Plaque Analysis Now Covered by Aetna Insurance Plans Nationwide and for the Majority of Insured Lives in the U.S. (GlobeNewswire)
Jan-05-26 04:05PM	Heartflow to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-25 11:53PM	Insiders Step in on These 2 Strong Buy Stocks And Analysts Are on the Same Page (TipRanks)
Dec-18-25 07:42PM	Why AI Stock HeartFlow Triumphed on Thursday (Motley Fool) +8.98% +6.49%
04:05PM	Heartflow Plaque Analysis Now Supported by Scientific Statements From American College of Cardiology and American Heart Association for Personalized Management of Patients with Suspected CAD (GlobeNewswire)
Dec-12-25 09:49AM	AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs (PR Newswire) -6.60%
Dec-11-25 03:10AM	Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease (GlobeNewswire)
Nov-19-25 04:33PM	Heartflow to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-12-25 04:22PM	HeartFlow: Q3 Earnings Snapshot (Associated Press Finance) -13.43%
04:01PM	Heartflow Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-09-25 01:30PM	AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification (GlobeNewswire)
Nov-04-25 07:06AM	Strong Investor Reception of IPO Boosted Heartflow (HTFL) in Q3 (Insider Monkey)
Nov-03-25 08:00AM	Heartflow to Present Late-Breaking Data Advancing AI-Driven Heartflow Plaque Analysis at AHA 2025 (GlobeNewswire) -8.38%
Oct-23-25 04:05PM	Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire) -5.11%
Oct-22-25 08:00AM	New Heartflow PCI Navigator to Equip Interventional Cardiologists with Pre-procedural Insights to Enable PCI Planning (GlobeNewswire) +7.27%
08:07AM	Loading…
Sep-29-25 08:07AM	HTFL Gains FDA Clearance & Cigna Coverage for Next Gen Plaque Analysis (Zacks)
Sep-23-25 06:55PM	Why HeartFlow Stock Rocketed 14% Higher Today (Motley Fool) +14.13%
Sep-22-25 04:05PM	Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform (GlobeNewswire)
Sep-19-25 05:28PM	HeartFlow: Q2 Earnings Snapshot (Associated Press Finance)
Sep-11-25 01:00AM	IPO Mania Is Back. Is It the Late 1990s All Over Again? (Barrons.com)
Sep-06-25 06:35AM	AI-Enabled Heart Diagnostics Put HeartFlow (HTFL) in the Spotlight (Insider Monkey)
Sep-04-25 10:20AM	Figma Stock Tumbles 20%. Why Its First Earnings Report Since IPO Was Disappointing. (Barrons.com) +8.97%
Sep-03-25 04:54PM	Figma Stock Tumbles. Why Its First Earnings Report Since IPO Was Disappointing. (Barrons.com)
04:54PM	Figma Stock Tumbles. What Disappointed in Its First Earnings Report Since Its IPO. (Barrons.com)
09:16AM	Figma's Earnings Will Be a Big Test for Software and IPOs (Barrons.com)
Sep-02-25 09:45AM	Elf Beauty downgraded, Zscaler upgraded: Wall Street's top analyst calls (The Fly)
Aug-27-25 04:24PM	Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire) +10.77% -7.54%
Aug-18-25 01:16PM	Gemini Files for an IPO. The Winklevoss Twins Are Behind This Crypto Exchange. (Barrons.com)
Aug-11-25 04:30PM	Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Aug-09-25 09:53AM	Heartflow (HTFL) Soars 66% on IPO on Strong Investor Confidence (Insider Monkey)
Aug-08-25 01:40PM	Heartflow shares surge in Nasdaq debut (Investing.com)
Jul-22-25 06:28PM	Heartflow Plaque Analysis to be Covered by UnitedHealthcare Plans Nationwide (GlobeNewswire)

HeartFlow, Inc. operates as a cardiovascular company which engages in diagnosing coronary artery diseases. The firm provides a patient-specific analysis of coronary blood flow utilizing coronary CT scans and proprietary computer algorithms based on computational fluid dynamics. The company was founded by Charles A. Taylor, Nathan M. Wilson, and Christopher K. Zarins in July 2007 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farquhar John C.M.	Chief Executive Officer	May 11 '26	Sale	29.12	22,562	657,005	519,397	May 13 06:23 PM
Farquhar John C.M.	Officer	May 11 '26	Proposed Sale	29.12	22,562	657,005		May 11 10:20 AM
Bain Capital Life Sciences Inv	10% Owner	Apr 30 '26	Sale	29.23	948,757	27,733,644	8,448,158	Apr 30 08:46 PM
Bain Capital Life Sciences Inv	10% Owner	Apr 29 '26	Sale	29.37	797,133	23,411,796	9,396,915	Apr 30 08:46 PM
Bain Capital Life Sciences Inv	10% Owner	Apr 28 '26	Sale	30.51	254,110	7,752,896	10,194,048	Apr 30 08:46 PM
Farquhar John C.M.	Chief Executive Officer	Apr 10 '26	Sale	26.72	22,562	602,857	549,163	Apr 14 05:53 PM
Farquhar John C.M.	Officer	Apr 10 '26	Proposed Sale	26.72	22,562	602,857		Apr 10 11:03 AM
Rogers Campbell	Chief Medical Officer	Apr 01 '26	Option Exercise	2.25	67,017	150,556	145,535	Apr 03 06:15 PM
Rogers Campbell	Chief Medical Officer	Apr 01 '26	Sale	24.64	64,533	1,590,093	81,002	Apr 03 06:15 PM
Rogers Campbell	Officer	Apr 01 '26	Proposed Sale	24.64	64,533	1,589,935		Apr 01 04:23 PM
Rogers Campbell	Chief Medical Officer	Mar 19 '26	Option Exercise	2.22	67,017	148,778	143,051	Mar 23 06:33 PM
Rogers Campbell	Chief Medical Officer	Mar 19 '26	Sale	25.69	64,533	1,658,033	78,518	Mar 23 06:33 PM
Farquhar John C.M.	Chief Executive Officer	Mar 18 '26	Sale	25.00	9,725	243,125	571,725	Mar 20 06:24 PM
Rogers Campbell	Officer	Mar 19 '26	Proposed Sale	25.69	64,533	1,658,030		Mar 19 04:23 PM
Farquhar John C.M.	Officer	Mar 18 '26	Proposed Sale	25.00	9,725	243,125		Mar 18 02:17 PM
BARABE TIMOTHY C	Director	Mar 11 '26	Option Exercise	2.22	8,667	19,241	179,521	Mar 12 07:57 PM
Farquhar John C.M.	Chief Executive Officer	Mar 10 '26	Sale	22.66	12,837	290,886	581,450	Mar 12 07:55 PM
Farquhar John C.M.	Officer	Mar 10 '26	Proposed Sale	22.66	12,837	290,886		Mar 10 10:53 AM
Cullivan Julie A	Director	Mar 05 '26	Sale	25.00	9,122	228,050	27,291	Mar 06 08:18 PM
Cullivan Julie A	Director	Mar 05 '26	Proposed Sale	25.00	9,122	228,050		Mar 05 02:11 PM
BARABE TIMOTHY C	Director	Feb 17 '26	Option Exercise	8.33	2,497	20,800	170,854	Feb 19 07:14 PM
Rogers Campbell	Chief Medical Officer	Feb 12 '26	Option Exercise	5.84	67,016	391,398	141,187	Feb 17 08:07 PM
Rogers Campbell	Chief Medical Officer	Feb 12 '26	Sale	24.49	65,153	1,595,486	76,034	Feb 17 08:07 PM
Rogers Campbell	Officer	Feb 12 '26	Proposed Sale	24.49	65,153	1,595,485		Feb 12 04:45 PM
Farquhar John C.M.	Chief Executive Officer	Feb 10 '26	Sale	27.46	22,562	619,553	591,656	Feb 10 08:24 PM
Farquhar John C.M.	Officer	Feb 10 '26	Proposed Sale	27.46	22,562	619,557		Feb 10 04:12 PM
Cullivan Julie A	Director	Feb 05 '26	Sale	27.32	8,000	218,560	36,413	Feb 06 09:42 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 04 '26	Sale	28.05	2,000,000	56,100,000	10,448,158	Feb 06 04:58 PM
Cullivan Julie A	Director	Feb 05 '26	Proposed Sale	27.32	8,000	218,560		Feb 05 09:58 AM
Lightcap Jeffrey C	Director	Dec 16 '25	Buy	26.34	40,000	1,053,680	40,000	Dec 17 06:43 PM

Open in Screener

KLRA

Kailera Therapeutics Inc

May 13 • 04:00PM ET

21.11

-1.19 -5.34 %

Healthcare • Biotechnology • USA • Mid • NASD

KLRA Kailera Therapeutics Inc daily Stock Chart

Peers: NTLA TWST RXRX VERA BEAM

| Held by: OZEM TNXT

Index	-	P/E	-	EPS (ttm)	-	Insider Own	32.50%	Shs Outstand	129.54M	Perf Week	-14.53%
Market Cap	2.73B	Forward P/E	-	EPS next Y	-3.55	Insider Trans	94.20%	Shs Float	87.44M	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	12.18%	Short Float	2.24%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-153.84%	Inst Trans	24.69%	Short Ratio	1.54	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-0.61%	ROA	-	Short Interest	1.95M	Perf YTD	-18.81%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	28.23 -25.21%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	20.86 1.17%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.11% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.03	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-11.70%	Beta	-	Target Price	42.75
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-11.70%	Rel Volume	0.28	Prev Close	22.30
Employees	145	LT Debt/Eq	-	Earnings	-	SMA200	-11.70%	Avg Volume	1.27M	Price	21.11
IPO	Apr 17, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	349,546	Change	-5.34%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-26	Initiated	William Blair	Outperform
May-12-26	Initiated	TD Cowen	Buy	$57
May-12-26	Initiated	Leerink Partners	Outperform	$36
May-12-26	Initiated	JP Morgan	Overweight	$30
May-12-26	Initiated	Jefferies	Buy	$48
May-12-26	Initiated	Evercore ISI	Outperform

Today 07:30AM	Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire) -5.34%
May-12-26 12:50PM	Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity (Investor's Business Daily)
Apr-20-26 04:05PM	Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.35%

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RTW INVESTMENTS, LP	10% Owner	Apr 20 '26	Buy	16.00	500,000	8,000,000	10,776,820	Apr 22 04:15 PM
BAIN CAPITAL INVESTORS LLC	10% Owner	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:10 PM
Koppel Adam	Director	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:08 PM
Bain Capital Life Sciences Inv	10% Owner	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:01 PM
Kaplan Andrew T.	Director	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:00 PM

Open in Screener

SLDB

Solid Biosciences Inc

May 13 • 04:00PM ET

7.38

-0.34 -4.40 %

Healthcare • Biotechnology • USA • Small • NASD

SLDB Solid Biosciences Inc daily Stock Chart

Peers: FDMT RCKT RGNX TNYA QURE

| Held by: VTI IWM IBB IWN VXF VTWO DFAS FESM DWAS DFMC

Index	RUT	P/E	-	EPS (ttm)	-1.95	Insider Own	13.77%	Shs Outstand	98.39M	Perf Week	2.50%
Market Cap	726.16M	Forward P/E	-	EPS next Y	-1.86	Insider Trans	-3.04%	Shs Float	84.85M	Perf Month	-10.33%
Enterprise Value	365.51M	PEG	-	EPS next Q	-0.44	Inst Own	67.07%	Short Float	10.38%	Perf Quarter	15.31%
Income	-191.78M	P/S	-	EPS this Y	6.91%	Inst Trans	-7.25%	Short Ratio	6.89	Perf Half Y	77.83%
Sales	0.00M	P/B	1.94	EPS next Y	-0.53%	ROA	-50.02%	Short Interest	8.81M	Perf YTD	30.85%
Book/sh	3.80	P/C	1.90	EPS next 5Y	14.50%	ROE	-57.37%	52W High	8.87 -16.76%	Perf Year	164.52%
Cash/sh	3.88	P/FCF	-	EPS past 3/5Y	41.79% 39.94%	ROIC	-48.85%	52W Low	2.41 206.22%	Perf 3Y	16.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.76% 5.80%	Perf 5Y	-88.92%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	34.94%	Oper. Margin	-	ATR (14)	0.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.10	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.95	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.10	EPS Q/Q	12.73%	SMA20	-3.56%	Beta	2.46	Target Price	17.17
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	-1.86%	Rel Volume	1.25	Prev Close	7.72
Employees	121	LT Debt/Eq	0.05	Earnings	May 12 AMC	SMA200	19.42%	Avg Volume	1.28M	Price	7.38
IPO	Jan 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21.33% -	Trades		Volume	1,595,510	Change	-4.40%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-26	Initiated	Guggenheim	Buy	$26
Dec-04-25	Initiated	Needham	Buy	$16
Jun-26-25	Initiated	Citigroup	Buy	$14
Jan-08-25	Initiated	Truist	Buy	$16
Dec-13-24	Initiated	Wedbush	Outperform	$16
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight	$10 → $15
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-31-24	Resumed	Piper Sandler	Overweight	$20
Mar-28-24	Initiated	William Blair	Outperform	$40
Mar-15-24	Initiated	Citigroup	Buy	$16
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $20
Dec-08-23	Initiated	H.C. Wainwright	Buy	$9
Jul-12-21	Initiated	Piper Sandler	Neutral	$6
May-27-21	Initiated	Jefferies	Buy	$7
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$3 → $15
Mar-09-21	Initiated	Barclays	Overweight	$13
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral	$2 → $7
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line

Show Previous Ratings

May-12-26 04:08PM	Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-26 08:00AM	Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy (GlobeNewswire)
May-01-26 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-26 08:00AM	Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (GlobeNewswire)
Apr-28-26 08:00AM	Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
08:00AM	Loading…
Apr-07-26 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Mar-19-26 04:12PM	Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-11-26 01:01PM	Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial (GlobeNewswire) -5.68%
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +18.81%
Mar-06-26 08:31AM	Solid Biosciences Announces Oversubscribed $240 Million Private Placement (GlobeNewswire) +20.32%
08:30AM	Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-02-26 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-26 05:35AM	Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreichs Ataxia Update (MarketBeat)
Feb-09-26 08:00AM	Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +5.21%
Feb-06-26 08:00AM	Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
02:49PM	Loading…
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 12:58PM	JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success (Pharmaceutical Technology)
Jan-13-26 04:15PM	Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 (GlobeNewswire) +12.60%
Jan-12-26 04:15PM	Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
08:05AM	Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Jan-06-26 08:00AM	Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-16-25 04:51PM	Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services (GlobeNewswire) -7.56%
Dec-15-25 11:10PM	Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy (Insider Monkey)
Dec-08-25 08:00AM	Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum (GlobeNewswire)
Dec-02-25 06:54AM	Solid Biosciences' SGT-212 gains FDA rare paediatric disease status (Pharmaceutical Business Review)
Dec-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Nov-17-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
08:00AM	Loading…
Nov-11-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +9.16%
Nov-06-25 08:00AM	Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +7.25%
Nov-04-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -15.29% -10.78%
Nov-03-25 04:05PM	Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions (GlobeNewswire)
Oct-30-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Present at Upcoming Scientific Meetings (GlobeNewswire)
Sep-25-25 08:00AM	Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting (GlobeNewswire) -5.13%
Sep-23-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Aug-28-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 04:07PM	Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +10.60%
03:33PM	Brutal 2025 for Sarepta-Analysts Still Call for 179% Upside (MarketBeat)
Aug-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-23-25 08:00AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +8.51%
Jul-21-25 08:30AM	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors (GlobeNewswire)
Jul-09-25 10:17AM	Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with 'Buy' Rating and $14 PT (Insider Monkey) +5.34%
Jul-08-25 04:05PM	Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +6.72%
Jul-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.54% +5.87%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-18-25 11:39AM	Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (MarketBeat)
Jun-03-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-25 08:00AM	Solid Biosciences to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.24%
May-15-25 04:06PM	Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.95%
May-01-25 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.27% +18.08%
Apr-30-25 08:00AM	Solid Biosciences to Participate at The Citizens Life Sciences Conference (GlobeNewswire) +8.52%
Apr-29-25 08:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting (GlobeNewswire) -5.57%
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -9.18%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
Apr-07-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) -5.62%
Apr-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.89%
07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha) -5.12%
Mar-14-25 10:29PM	Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month (Insider Monkey) +5.30%
Mar-12-25 08:00AM	Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-07-25 09:55AM	Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade (Zacks)
Mar-06-25 04:16PM	Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +8.47%
Mar-04-25 08:33PM	Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
04:07PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 08:02AM	Solid Biosciences stock soars on early success in DMD gene therapy trial (Clinical Trials Arena) +22.08%
Feb-18-25 07:00AM	Solid Biosciences Announces Pricing of Underwritten Offering (GlobeNewswire) +31.51%
06:45AM	Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 (GlobeNewswire)
06:36AM	Solid says early data suggest differentiated Duchenne gene therapy (BioPharma Dive)
Feb-09-25 06:12AM	Analysts Predict Up to ~450% Surge for These 2 Strong Buy Penny Stocks (TipRanks)
Feb-04-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-25 08:30AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Jan-15-25 04:05PM	Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines (GlobeNewswire)
Jan-08-25 04:05PM	Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.68%
Jan-07-25 04:15PM	Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia (GlobeNewswire)
Jan-06-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-23-24 04:05PM	Solid Biosciences Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-13-24 01:52PM	Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst (Benzinga)
Dec-04-24 08:05AM	Solid Biosciences reports inducement grant under Nasdaq listing rule (TipRanks)
08:00AM	Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies (GlobeNewswire)
Dec-03-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.54%
Nov-26-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 08:00AM	Solid Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-24 04:05PM	Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.03%
Nov-04-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-24 08:00AM	Solid Biosciences to Participate at the Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-02-24 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-23-24 08:00AM	Solid Biosciences to Participate at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-12-24 08:00AM	Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 04:08PM	Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +14.54%
Aug-05-24 08:00AM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 04:19PM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.58%
08:00AM	Solid Biosciences Joins the Russell 3000 Index (GlobeNewswire)

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cumbo Alexander	President and CEO	Feb 18 '26	Sale	5.82	16,644	96,923	235,405	Feb 18 09:38 PM
Brooks Gabriel	Officer	Feb 18 '26	Proposed Sale	5.82	5,563	32,395		Feb 18 09:35 PM
Cumbo Alexander	Officer	Feb 18 '26	Proposed Sale	5.82	16,644	96,923		Feb 18 09:35 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 18 '26	Sale	5.82	4,134	24,074	74,318	Feb 18 09:34 PM
Hanrahan Jessie	Officer	Feb 18 '26	Proposed Sale	5.82	4,134	24,074		Feb 18 09:33 PM
Ganot Ilan	Director	Feb 18 '26	Sale	5.82	2,658	15,478	27,474	Feb 18 09:32 PM
Herzich Paul	Officer	Feb 18 '26	Proposed Sale	5.82	3,616	21,057		Feb 18 09:32 PM
Ganot Ilan	Director	Feb 18 '26	Proposed Sale	5.92	2,658	15,748		Feb 18 09:31 PM
Herzich Paul	Chief Technology Officer	Feb 18 '26	Sale	5.82	3,616	21,057	72,638	Feb 18 09:31 PM
Howton David T	Chief Operating Officer	Feb 18 '26	Sale	5.82	7,469	43,494	105,077	Feb 18 09:31 PM
Howton David T	Officer	Feb 18 '26	Proposed Sale	5.82	7,469	43,494		Feb 18 09:30 PM
Tan Kevin	Officer	Feb 18 '26	Proposed Sale	5.82	5,404	31,469		Feb 18 09:28 PM
Tan Kevin	CFO & Treasurer	Feb 18 '26	Sale	5.82	5,404	31,469	99,422	Feb 18 09:25 PM
Howton David T	Chief Operating Officer	Feb 04 '26	Sale	6.44	18,894	121,713	97,859	Feb 06 06:05 PM
Cumbo Alexander	President and CEO	Feb 04 '26	Sale	6.44	48,913	315,093	222,018	Feb 06 06:01 PM
Ganot Ilan	Director	Feb 04 '26	Sale	6.44	7,205	46,414	25,271	Feb 06 06:01 PM
Tan Kevin	CFO & Treasurer	Feb 04 '26	Sale	6.44	14,783	95,231	94,201	Feb 06 06:00 PM
Brooks Gabriel	Chief Medical Officer	Feb 04 '26	Sale	6.44	12,616	81,271	84,092	Feb 06 05:59 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 04 '26	Sale	6.44	12,348	79,545	70,327	Feb 06 05:57 PM
Herzich Paul	Chief Technology Officer	Feb 04 '26	Sale	6.44	10,905	70,249	69,067	Feb 06 05:56 PM
Tan Kevin	Officer	Feb 04 '26	Proposed Sale	6.44	14,783	95,227		Feb 04 07:48 PM
Herzich Paul	Officer	Feb 04 '26	Proposed Sale	6.44	10,905	70,247		Feb 04 07:46 PM
Ganot Ilan	Director	Feb 04 '26	Proposed Sale	6.44	7,205	46,412		Feb 04 07:45 PM
Cumbo Alexander	Officer	Feb 04 '26	Proposed Sale	6.44	48,913	315,080		Feb 04 07:44 PM
Howton David T	Officer	Feb 04 '26	Proposed Sale	6.44	18,894	121,708		Feb 04 07:42 PM
Hanrahan Jessie	Officer	Feb 04 '26	Proposed Sale	6.44	12,348	79,541		Feb 04 07:40 PM
Brooks Gabriel	Officer	Feb 04 '26	Proposed Sale	6.44	12,616	81,268		Feb 04 07:37 PM
Tan Kevin	CFO & Treasurer	Feb 02 '26	Sale	6.44	26,837	172,747	108,984	Feb 02 08:18 PM
Cumbo Alexander	President and CEO	Feb 02 '26	Sale	6.44	80,258	516,613	270,931	Feb 02 08:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 02 '26	Sale	6.44	26,535	170,803	82,675	Feb 02 08:15 PM
Brooks Gabriel	Chief Medical Officer	Feb 02 '26	Sale	6.44	28,335	182,390	96,708	Feb 02 08:14 PM
Howton David T	Chief Operating Officer	Feb 02 '26	Sale	6.44	37,771	243,128	116,753	Feb 02 08:12 PM
Herzich Paul	Chief Technology Officer	Feb 02 '26	Sale	6.44	26,250	168,969	79,972	Feb 02 08:09 PM
Hanrahan Jessie	Officer	Feb 02 '26	Proposed Sale	6.44	26,535	170,803		Feb 02 08:07 PM
Brooks Gabriel	Officer	Feb 02 '26	Proposed Sale	6.44	28,335	182,390		Feb 02 08:05 PM
Tan Kevin	Officer	Feb 02 '26	Proposed Sale	6.44	26,837	172,747		Feb 02 08:04 PM
Cumbo Alexander	Officer	Feb 02 '26	Proposed Sale	6.44	80,258	516,613		Feb 02 08:03 PM
Howton David T	Officer	Feb 02 '26	Proposed Sale	6.44	37,771	243,128		Feb 02 08:01 PM
Herzich Paul	Officer	Feb 02 '26	Proposed Sale	6.44	26,250	168,969		Feb 02 07:59 PM
Ganot Ilan	Director	Jan 28 '26	Sale	6.59	191	1,259	17,476	Jan 30 04:05 PM
Tan Kevin	CFO & Treasurer	Jan 13 '26	Sale	5.27	5,704	30,060	46,100	Jan 13 05:02 PM
Tan Kevin	Officer	Jan 13 '26	Proposed Sale	5.27	5,704	30,060		Jan 13 05:00 PM
Ganot Ilan	Director	Jan 05 '26	Sale	5.43	1,053	5,718	17,278	Jan 06 06:52 PM
Howton David T	Chief Operating Officer	Dec 03 '25	Sale	5.11	4,932	25,203	32,908	Dec 04 04:22 PM
Cumbo Alexander	President and CEO	Dec 03 '25	Sale	5.11	10,808	55,229	81,388	Dec 04 04:20 PM
Hanrahan Jessie	Chief Regulatory Officer	Dec 03 '25	Sale	5.11	4,483	22,908	26,660	Dec 04 04:19 PM
Herzich Paul	Chief Technology Officer	Dec 03 '25	Sale	5.11	2,701	13,802	26,622	Dec 04 04:17 PM
Cumbo Alexander	Officer	Dec 03 '25	Proposed Sale	5.11	10,808	55,229		Dec 03 05:07 PM
Ganot Ilan	Director	Nov 10 '25	Sale	4.12	3,278	13,505	95,412	Nov 13 04:05 PM
Brooks Gabriel	Chief Medical Officer	Oct 20 '25	Sale	5.96	2,895	17,254	33,819	Oct 21 04:05 PM

Open in Screener

OLMA

Olema Pharmaceuticals Inc

May 13 • 04:00PM ET

13.58

-0.39 -2.79 %

Healthcare • Biotechnology • USA • Small • NASD

OLMA Olema Pharmaceuticals Inc daily Stock Chart

Peers: ARVN KYMR RLAY ORIC NUVB

| Held by: XBI VTI IWM IWN VXF IBB VTWO DFAS SCHA DFMC

Index	RUT	P/E	-	EPS (ttm)	-2.03	Insider Own	20.65%	Shs Outstand	87.33M	Perf Week	-10.60%
Market Cap	1.18B	Forward P/E	-	EPS next Y	-2.32	Insider Trans	-4.54%	Shs Float	69.16M	Perf Month	-16.69%
Enterprise Value	682.20M	PEG	-	EPS next Q	-0.55	Inst Own	90.30%	Short Float	18.86%	Perf Quarter	-42.58%
Income	-185.15M	P/S	-	EPS this Y	-17.88%	Inst Trans	18.55%	Short Ratio	8.77	Perf Half Y	56.09%
Sales	0.00M	P/B	2.47	EPS next Y	-5.04%	ROA	-39.38%	Short Interest	13.04M	Perf YTD	-45.68%
Book/sh	5.50	P/C	2.34	EPS next 5Y	-2.32%	ROE	-42.86%	52W High	36.26 -62.55%	Perf Year	190.17%
Cash/sh	5.80	P/FCF	-	EPS past 3/5Y	10.68% -25.06%	ROIC	-38.30%	52W Low	3.89 249.10%	Perf 3Y	94.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.37% 5.60%	Perf 5Y	-43.58%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.36%	Oper. Margin	-	ATR (14)	0.93	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.88	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	32.63	Recom	1.15
Dividend Gr. 3/5Y	- -	Current Ratio	10.88	EPS Q/Q	-45.18%	SMA20	-10.45%	Beta	2.05	Target Price	42.36
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-12.94%	Rel Volume	0.85	Prev Close	13.97
Employees	131	LT Debt/Eq	0.01	Earnings	May 12 BMO	SMA200	-16.54%	Avg Volume	1.49M	Price	13.58
IPO	Nov 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.02% -	Trades		Volume	1,266,406	Change	-2.79%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	Wolfe Research	Peer Perform
Mar-19-26	Resumed	Jefferies	Buy
Feb-11-26	Initiated	Stifel	Buy	$48
Jan-07-26	Initiated	Piper Sandler	Overweight	$40
Oct-08-25	Initiated	Guggenheim	Buy	$20
Aug-12-25	Reiterated	Citigroup	Buy	$20 → $21
Apr-02-24	Initiated	Goldman	Buy	$24
Jan-30-24	Initiated	Citigroup	Buy	$20
Jul-21-23	Initiated	Oppenheimer	Outperform	$21
May-05-23	Initiated	CapitalOne	Overweight	$16
Feb-22-23	Initiated	Credit Suisse	Outperform	$12
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight	$52
Dec-14-20	Initiated	Jefferies	Buy	$70
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy	$60

Show Previous Ratings

May-12-26 07:00AM	Olema Oncology Reports First Quarter 2026 Financial and Operating Results (GlobeNewswire) -5.99%
May-04-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-26 04:01PM	Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors (GlobeNewswire)
Apr-21-26 04:01PM	Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-17-26 04:01PM	Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting (GlobeNewswire)
04:30PM	Loading…
Apr-02-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-17-26 04:30PM	Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting (GlobeNewswire) -9.31%
Mar-16-26 07:00AM	Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire) +12.85%
Mar-09-26 12:22PM	Why Is Olema Pharmaceuticals Stock Dropping On Monday? (Benzinga) -25.75%
11:15AM	Roche Tumbles, Taking Olema With It, On A High-Profile Failure (Investor's Business Daily)
Mar-03-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-26 03:05AM	Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at Conference (MarketBeat)
Feb-27-26 04:05PM	Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure (Insider Monkey)
Feb-24-26 04:39AM	Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit (MarketBeat)
Feb-19-26 04:30PM	Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +6.25%
12:23PM	Loading…
Feb-16-26 12:23PM	Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating (Insider Monkey)
Feb-14-26 01:02PM	Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit (MarketBeat)
Feb-04-26 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
Feb-03-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-26 04:01PM	Olema Oncology Announces Departure of Chief Operating and Financial Officer (GlobeNewswire)
09:47AM	LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) (Insider Monkey)
Jan-21-26 05:59AM	Piper Sandler Puts its Weight Behind 2 Strong Buy Cancer Stocks (TipRanks)
Jan-05-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 10:19AM	Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT (Insider Monkey)
Dec-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 05:45PM	This strategist is 'following the money' on these stock picks (Yahoo Finance Video) +8.11%
Nov-21-25 04:30PM	Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.27%
Nov-20-25 04:01PM	Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.28%
Nov-19-25 11:50AM	Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here? (Barchart)
07:00AM	Loading…
07:00AM	Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock (GlobeNewswire)
Nov-18-25 04:51PM	Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +136.38%
04:21PM	Why biotech and drug stocks are on the mend even though the rest of the market is hurting (MarketWatch)
09:20AM	Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% (Investor's Business Daily)
Nov-10-25 07:00AM	Olema Oncology Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.13%
Oct-30-25 04:30PM	Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 (GlobeNewswire)
Oct-18-25 03:00AM	Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 (GlobeNewswire)
Oct-16-25 04:33PM	Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential (Insider Monkey) -7.43%
Oct-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 11:41AM	Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) (Insider Monkey)
Sep-12-25 10:38AM	OLMA Stock Soars 47% in September So Far on Second PFE Deal (Zacks)
Sep-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 07:00AM	Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer (GlobeNewswire) +18.50%
Aug-20-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
Aug-13-25 01:15AM	Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals (Insider Monkey)
Aug-11-25 04:01PM	Olema Oncology Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire) +16.19%
Aug-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.43%
May-28-25 07:00AM	Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting (GlobeNewswire)
May-21-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? (Zacks)
May-13-25 04:01PM	Olema Oncology Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-09-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
Apr-25-25 01:00PM	Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 (GlobeNewswire)
Apr-24-25 09:55AM	Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet (Zacks)
Apr-10-25 09:35AM	After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA) (Zacks) +8.25%
Apr-08-25 04:25PM	Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market (Seeking Alpha)
Apr-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-25 04:31PM	Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-18-25 04:01PM	Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire) -6.97%
Mar-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 04:30PM	Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 07:00AM	Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Feb-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46%
Feb-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.75% -6.62%
Jan-02-25 07:00AM	Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 07:00AM	Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 07:00AM	Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor (GlobeNewswire) -9.67%
Dec-03-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:17AM	Novartis and Olema expand alliance with $250m to boost breast cancer trials (Pharmaceutical Technology)
Dec-02-24 07:00AM	Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement (GlobeNewswire)
Nov-25-24 05:30PM	Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire) +9.09%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-12-24 04:01PM	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.28%
Nov-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 04:44PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 (GlobeNewswire)
Oct-09-24 07:00AM	Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:49PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 07:00AM	Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:02PM	Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.90%
Aug-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.22%
Aug-01-24 08:50AM	Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why (Zacks)
Jul-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-04-24 04:28PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.96%
May-28-24 07:03AM	Olema Oncology to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-15-24 07:01AM	Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress (GlobeNewswire)
May-08-24 10:58PM	OLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) -9.31%
04:02PM	Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:02AM	Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire) +5.96%
May-02-24 04:37PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kovacs Shane William Charles	Former Officer	Mar 16 '26	Proposed Sale	16.61	4,166	69,178		Mar 16 04:03 PM
Kovacs Shane William Charles	Former Officer	Mar 16 '26	Proposed Sale	16.08	100,000	1,607,719		Mar 16 12:43 PM
Kovacs Shane William Charles	Former Officer	Mar 11 '26	Proposed Sale	15.94	50,000	796,796		Mar 11 04:20 PM
Kovacs Shane William Charles	Former Officer	Mar 10 '26	Proposed Sale	17.00	53,206	904,566		Mar 10 12:27 PM
Kovacs Shane William Charles	Former Officer	Mar 09 '26	Proposed Sale	13.45	241,999	3,254,933		Mar 09 03:16 PM
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 04 '26	Option Exercise	4.37	25,000	109,250	25,000	Mar 05 08:00 PM
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 03 '26	Option Exercise	4.37	15,000	65,550	15,000	Mar 05 08:00 PM
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 04 '26	Sale	24.25	25,000	606,353	0	Mar 05 08:00 PM
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 03 '26	Sale	23.01	15,000	345,150	0	Mar 05 08:00 PM
Kovacs Shane William Charles	Former Officer	Mar 04 '26	Proposed Sale	24.43	20,000	488,654		Mar 04 02:19 PM
Mitchell Shawnte	Officer	Mar 04 '26	Proposed Sale	23.94	25,000	598,500		Mar 04 10:21 AM
Mitchell Shawnte	Officer	Mar 03 '26	Proposed Sale	23.01	15,000	345,153		Mar 03 02:59 PM
Kovacs Shane William Charles	Former Officer	Feb 27 '26	Proposed Sale	25.00	6,521	163,026		Feb 27 04:38 PM
Kovacs Shane William Charles	Former Officer	Feb 24 '26	Proposed Sale	25.00	20,000	500,002		Feb 24 03:46 PM
Kovacs Shane William Charles	Former Officer	Feb 23 '26	Proposed Sale	24.30	10,000	243,000		Feb 23 04:33 PM
Kovacs Shane William Charles	Former Officer	Feb 23 '26	Proposed Sale	24.00	20,000	480,007		Feb 23 02:34 PM
Kovacs Shane William Charles	Former Officer	Feb 12 '26	Proposed Sale	23.85	10,000	238,498		Feb 12 02:55 PM
Harmon Cyrus	Director	Jan 20 '26	Sale	26.88	10,000	268,800	727,770	Jan 21 09:00 PM
Harmon Cyrus	Director	Jan 20 '26	Proposed Sale	26.88	10,000	268,763		Jan 20 04:13 PM
Harmon Cyrus	Director	Jan 14 '26	Sale	29.12	3,489	101,600	737,770	Jan 16 09:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 15 '26	Sale	28.73	100,000	2,873,000	139,727	Jan 15 09:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 13 '26	Sale	28.01	3,822	107,054	239,727	Jan 15 09:00 PM
Kovacs Shane William Charles	Officer	Jan 15 '26	Proposed Sale	28.73	100,000	2,873,215		Jan 15 04:22 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Sale	28.87	50,000	1,443,651	542,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Sale	27.60	50,000	1,380,178	542,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 12 '26	Sale	28.34	10,000	283,400	144,846	Jan 14 09:30 PM
Harmon Cyrus	Director	Jan 14 '26	Proposed Sale	29.12	3,489	101,603		Jan 14 04:20 PM
Myles David C.	Officer	Jan 14 '26	Proposed Sale	28.87	50,000	1,443,631		Jan 14 04:13 PM
Kovacs Shane William Charles	Officer	Jan 13 '26	Proposed Sale	28.01	3,822	107,069		Jan 13 04:49 PM
Myles David C.	Officer	Jan 13 '26	Proposed Sale	27.60	50,000	1,380,113		Jan 13 04:12 PM
Myles David C.	Officer	Jan 12 '26	Proposed Sale	28.34	10,000	283,363		Jan 12 12:53 PM
Harmon Cyrus	Director	Dec 22 '25	Sale	28.53	2,881	82,195	741,259	Dec 29 09:55 PM
CLARK IAN T	Director	Dec 19 '25	Option Exercise	4.61	264,800	1,219,544	264,800	Dec 23 09:42 PM
CLARK IAN T	Director	Dec 19 '25	Sale	29.73	264,800	7,873,109	0	Dec 23 09:42 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 19 '25	Sale	30.46	51,000	1,553,544	551,881	Dec 23 09:41 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Option Exercise	14.07	50,000	703,392	153,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Option Exercise	15.25	40,000	610,000	173,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Option Exercise	7.02	50,000	351,000	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Sale	28.04	100,000	2,804,000	53,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Sale	27.66	99,509	2,752,419	4,488	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Sale	28.20	70,000	1,973,729	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Officer	Dec 23 '25	Proposed Sale	27.66	99,509	2,752,165		Dec 23 01:31 PM
Harmon Cyrus	Officer	Dec 22 '25	Proposed Sale	28.53	2,881	82,182		Dec 22 04:09 PM
Zojwalla Naseem	Officer	Dec 22 '25	Proposed Sale	28.04	100,000	2,804,039		Dec 22 02:14 PM
Myles David C.	Officer	Dec 19 '25	Proposed Sale	30.46	51,000	1,553,447		Dec 19 04:33 PM
Zojwalla Naseem	Officer	Dec 19 '25	Proposed Sale	28.19	70,000	1,973,561		Dec 19 04:29 PM
CLARK IAN T	Director	Dec 19 '25	Proposed Sale	29.73	264,800	7,873,502		Dec 19 02:35 PM
RAPPAPORT ANDREW	Director	Nov 21 '25	Option Exercise	0.39	35,868	13,989	35,868	Nov 25 06:00 PM
Harmon Cyrus	Director	Sep 18 '25	Sale	8.33	10,000	83,300	744,140	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 16 '25	Sale	8.04	10,000	80,400	754,140	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 18 '25	Sale	8.32	3,086	25,676	117,028	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 16 '25	Sale	8.08	1,914	15,465	120,114	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 18 '25	Proposed Sale	8.33	13,086	108,978		Sep 18 02:08 PM
Harmon Cyrus	Director	Sep 16 '25	Proposed Sale	8.04	11,914	95,827		Sep 16 04:39 PM

HTFL

Heartflow Inc

KLRA

Kailera Therapeutics Inc

SLDB

Solid Biosciences Inc

OLMA

Olema Pharmaceuticals Inc

Upgrade your Finviz experience